HRP20211356T1 - Optimizacija topivosti imunoveziva - Google Patents

Optimizacija topivosti imunoveziva Download PDF

Info

Publication number
HRP20211356T1
HRP20211356T1 HRP20211356TT HRP20211356T HRP20211356T1 HR P20211356 T1 HRP20211356 T1 HR P20211356T1 HR P20211356T T HRP20211356T T HR P20211356TT HR P20211356 T HRP20211356 T HR P20211356T HR P20211356 T1 HRP20211356 T1 HR P20211356T1
Authority
HR
Croatia
Prior art keywords
amino acid
heavy chain
chain amino
acid position
threonine
Prior art date
Application number
HRP20211356TT
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211356(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20211356T1 publication Critical patent/HRP20211356T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Claims (3)

1. Imuno vezivo koje sadrži sljedeće motive za povećanje topivosti u položajima aminokiselina teškog lanca 12, 103 i 144 (numeriranje AHo): (a1) Serin (S) na aminokiselini teškog lanca 12; (b1) Treonin (T) na položaju aminokiseline teškog lanca 103; i (c1) Serin (S) na položaju aminokiselina teškog lanca 144; ili (a2) Serin (S) na aminokiselini teškog lanca 12; (b2) Treonin (T) na položaju aminokiseline teškog lanca 103; i (c2) Treonin (T) na položaju aminokiselina teškog lanca 144, gdje je imuno vezivo scFv antitijelo, imunoglobulin pune dužine ili nanotijelo.
2. Imuno vezivo prema zahtjevu 1, naznačeno time da se imuno vezivo specifično veže na humani TNFa ili na ljudski VEGF.
3. Pripravak koji sadrži imuno vezivo prema zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač.
HRP20211356TT 2008-06-25 2021-08-25 Optimizacija topivosti imunoveziva HRP20211356T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
EP17161990.1A EP3241843B1 (en) 2008-06-25 2009-06-25 Solubility optimization of immunobinders

Publications (1)

Publication Number Publication Date
HRP20211356T1 true HRP20211356T1 (hr) 2021-11-26

Family

ID=41228195

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171250TT HRP20171250T1 (hr) 2008-06-25 2017-08-16 Optimiziranje topivosti imunoveznih sredstava
HRP20211356TT HRP20211356T1 (hr) 2008-06-25 2021-08-25 Optimizacija topivosti imunoveziva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20171250TT HRP20171250T1 (hr) 2008-06-25 2017-08-16 Optimiziranje topivosti imunoveznih sredstava

Country Status (21)

Country Link
US (3) US9556265B2 (hr)
EP (2) EP3241843B1 (hr)
JP (3) JP5745720B2 (hr)
KR (2) KR101650165B1 (hr)
CN (2) CN102076715B (hr)
AU (1) AU2009264566B2 (hr)
BR (1) BRPI0914666A2 (hr)
CA (1) CA2728829C (hr)
CY (2) CY1119626T1 (hr)
DK (2) DK2307455T3 (hr)
ES (2) ES2884117T3 (hr)
HR (2) HRP20171250T1 (hr)
HU (2) HUE034827T2 (hr)
LT (2) LT3241843T (hr)
MX (2) MX346024B (hr)
PL (2) PL2307455T3 (hr)
PT (2) PT3241843T (hr)
RU (3) RU2514658C2 (hr)
SI (2) SI2307455T1 (hr)
WO (1) WO2009155725A1 (hr)
ZA (1) ZA201008595B (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
CA2777527C (en) * 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20130310281A1 (en) * 2011-02-02 2013-11-21 Glaxo Group Limited Novel antigen binding proteins
KR102345999B1 (ko) 2012-11-05 2021-12-30 델레넥스 쎄라퓨틱스 아게 Il-1 베타 결합성분
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
RU2015139095A (ru) * 2013-02-15 2017-03-21 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Акцепторный каркасный участок для пересадки cdr
RU2015139890A (ru) * 2013-02-20 2017-03-27 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Акцепторный каркасный участок для пересадки cdr
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
JP6580570B2 (ja) * 2013-09-06 2019-09-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体安定性を向上させるための方法
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
ES2685917T3 (es) * 2015-10-21 2018-10-15 Trinseo Europe Gmbh Dienos funcionalizados con aminosilano para el uso en la funcionalización de polímeros elastoméricos
CN116082505A (zh) 2016-02-25 2023-05-09 细胞医学公司 Pd-l1的结合成员
AU2022219517A1 (en) 2021-02-12 2023-07-13 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
WO2022190007A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries
KR20230169944A (ko) 2021-03-09 2023-12-18 씨디알-라이프 아게 Mage-a4 펩티드-mhc 항원 결합 단백질
WO2023110918A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
US20240091262A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag Mage-a4 peptide dual t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1946775A3 (en) 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
EP1242457B1 (en) 1999-12-28 2004-08-11 Esbatech AG Intrabodies with defined framework that is stable in a reducing environment and applications thereof
MXPA02008178A (es) * 2000-02-25 2004-04-05 Us Gov Health & Human Serv Scfvs anti-egfrviii con citotoxicidad y rendimiento mejorados, inmunotoxinas en base a los mismos y metodos para su uso.
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
ES2399617T3 (es) 2002-05-22 2013-04-02 Esbatech - A Novartis Company Llc Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas
RS20150135A1 (en) * 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
EP1773872B1 (en) 2004-05-21 2017-03-15 The Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
DK2164961T3 (en) 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sequence based forward position and optimization of single chain ​​antibodies
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders

Also Published As

Publication number Publication date
CY1124644T1 (el) 2022-07-22
KR101790567B1 (ko) 2017-10-26
CN102076715B (zh) 2018-06-19
US20170096482A1 (en) 2017-04-06
WO2009155725A1 (en) 2009-12-30
ES2629345T3 (es) 2017-08-08
PT3241843T (pt) 2021-09-10
JP2011525496A (ja) 2011-09-22
SI3241843T1 (sl) 2021-11-30
EP2307455B1 (en) 2017-03-22
CA2728829A1 (en) 2009-12-30
DK3241843T3 (da) 2021-09-06
US20110268728A1 (en) 2011-11-03
US20190169284A1 (en) 2019-06-06
JP5745720B2 (ja) 2015-07-08
LT3241843T (lt) 2021-09-27
KR101650165B1 (ko) 2016-08-22
PL2307455T3 (pl) 2017-09-29
RU2014104577A (ru) 2015-08-20
US10221237B2 (en) 2019-03-05
CN105418763A (zh) 2016-03-23
EP3241843A1 (en) 2017-11-08
MX346024B (es) 2017-03-02
PL3241843T3 (pl) 2021-12-27
BRPI0914666A2 (pt) 2015-10-20
RU2514658C2 (ru) 2014-04-27
JP2016128517A (ja) 2016-07-14
SI2307455T1 (sl) 2017-07-31
CN102076715A (zh) 2011-05-25
EP2307455A1 (en) 2011-04-13
PT2307455T (pt) 2017-07-03
HUE034827T2 (en) 2018-03-28
CA2728829C (en) 2018-01-02
RU2653441C2 (ru) 2018-05-08
US11046757B2 (en) 2021-06-29
KR20110022714A (ko) 2011-03-07
LT2307455T (lt) 2017-06-26
ZA201008595B (en) 2012-02-29
EP3241843B1 (en) 2021-07-28
HUE056090T2 (hu) 2022-01-28
DK2307455T3 (en) 2017-07-10
US9556265B2 (en) 2017-01-31
CY1119626T1 (el) 2018-04-04
AU2009264566A1 (en) 2009-12-30
RU2011102548A (ru) 2012-07-27
AU2009264566B2 (en) 2014-05-08
HRP20171250T1 (hr) 2017-10-20
ES2884117T3 (es) 2021-12-10
JP2014111667A (ja) 2014-06-19
MX2011000074A (es) 2011-02-24
RU2018112257A (ru) 2019-10-09
KR20160083129A (ko) 2016-07-11

Similar Documents

Publication Publication Date Title
HRP20211356T1 (hr) Optimizacija topivosti imunoveziva
NZ701040A (en) Covalently linked antigen-antibody conjugates
RS53270B (en) MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEINS AND THEIR USE
CY2017043I1 (el) Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
HRP20211343T1 (hr) Protutijela protiv dkk-1
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
MX2022006074A (es) Conjugados y anticuerpos manipulados geneticamente con cisteina.
TR201818881T4 (tr) Sinyal Amplifikasyonu İmmünodeneyleri
HRP20180078T1 (hr) VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE
BRPI1012694A2 (pt) anticorpos solúveis apenas com cadeia pesada
WO2011133704A3 (en) Modified polypeptides and proteins and uses thereof
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
NO20091576L (no) Sammensetninger av TRL-ligander og antiviraler
BRPI0818780A2 (pt) Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
BR112016000303A2 (pt) partícula tipo viral que compreende antígeno pd-1 ou antígeno ligante pd-1, molécula de ácido nucleico isolada, vetor, composição farmacêutica, uso dos mesmos, e kit
FR2921928B1 (fr) Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BRPI0919841A2 (pt) Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
NZ602220A (en) Antibodies with ph dependent antigen binding
BRPI0819598A2 (pt) anticorpos para o antígeno pcrv da pseudomonas aeruginosa
DK1996625T3 (da) Anti-Tat226 antistoffer og immunkonjugater
BRPI0922885A2 (pt) anticorpos humanos de alta afinidade para a pcsk9.
NL1031674A1 (nl) Antilichamen tegen myostatine.